TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34960061

Group type: EXPERIMENTAL
Intervention: LC-Plasma tablets (approximately 100 billion cells/day) for 8 weeks
Number of subjects: 320

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320
Study: 32316993

Group type: EXPERIMENTAL
Intervention: Onsite molecular testing using GeneXpert Edge, process redesign to facilitate same-day TB diagnosis and treatment, and performance feedback
Number of subjects: 20

Group type: COMPARATOR
Intervention: Routine care (onsite sputum smear microscopy plus referral of sputum samples to Xpert testing sites)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Onsite molecular testing using GeneXpert Edge
Number of subjects: 20

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 20
Study: 34995992

Group type: EXPERIMENTAL
Intervention: Escitalopram monotherapy for 8-12 weeks
Number of subjects: 85
Study: 32490758

Group type: EXPERIMENTAL
Intervention: Progress feedback group
Number of subjects: 159

Group type: COMPARATOR
Intervention: Non-feedback group
Number of subjects: 159
Study: 35567598

Group type: EXPERIMENTAL
Intervention: HNP-3
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: hBD-2
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: LL-37
Number of subjects: 66
Study: 34843068

Group type: EXPERIMENTAL
Intervention: Entecavir treatment
Number of subjects: 161
Study: 35212574

Group type: COMPARATOR
Intervention: Systemic therapy alone
Number of subjects: 1910

Group type: EXPERIMENTAL
Intervention: Up-front cytoreductive nephrectomy (uCN)
Number of subjects: 1910

Group type: EXPERIMENTAL
Intervention: Deferred cytoreductive nephrectomy (dCN)
Number of subjects: 1910

Group type: EXPERIMENTAL
Intervention: Cytoreductive nephrectomy (CN) with systemic therapy
Number of subjects: 1910
Study: 34107013

Group type: EXPERIMENTAL
Intervention: Upadacitinib 45 mg once daily (QD)
Number of subjects: 250
Study: 33021715

Group type: EXPERIMENTAL
Intervention: Antihypertensive drug and lifestyle intervention therapies
Number of subjects: 2912

Group type: COMPARATOR
Intervention: Standard antihypertensive drug intervention therapy
Number of subjects: 2912
Study: 35841009

Group type: EXPERIMENTAL
Intervention: Life skills training based on self-care (8 sessions)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study: 33530473

Group type: EXPERIMENTAL
Intervention: ECG recording device with artefact correction methods (1, 3, and 6% missed beats)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Polar H7 recording device
Number of subjects: 17
Study: 32063109

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (two 600 mg tablets)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 32
Study: 36349391

Group type: EXPERIMENTAL
Intervention: CO2 laser treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham application
Number of subjects: 60
Study: 33632752

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 918

Group type: EXPERIMENTAL
Intervention: Minimally invasive ablative therapy to prostate±pelvic lymph node dissection (PLND)
Number of subjects: 918

Group type: EXPERIMENTAL
Intervention: Cytoreductive radical prostatectomy±PLND OR prostate radiotherapy±pelvic lymph node radiotherapy (PLNRT)
Number of subjects: 918

Group type: EXPERIMENTAL
Intervention: All arms will receive standard systemic therapy with ADT±upfront systemic chemotherapy or androgen receptor agents.
Number of subjects: 918
Study: 33026741

Group type: EXPERIMENTAL
Intervention: Recombinant interferon beta‐1b plus lopinavir‐ritonavir
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Recombinant interferon beta‐1b plus lopinavir‐ritonavir (within 7 days after symptom onset)
Number of subjects: 95
Study: 33900213

Group type: EXPERIMENTAL
Intervention: Peripheral nerve block (PNB)
Number of subjects: 197
Study: 35956235

Group type: EXPERIMENTAL
Intervention: Physical exercise intervention conducted one month after bariatric surgery
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 43
Study: 33451959

Group type: EXPERIMENTAL
Intervention: Wheat straw chopped at 1 mm GMPL (fine PS)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Wheat straw at 4 mm GMPL (medium PS)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Wheat straw at 7 mm GMPL (long PS)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Starter without wheat straw supplementation (CON)
Number of subjects: 48
Study: 34627871

Group type: EXPERIMENTAL
Intervention: Resolution of hydronephrosis
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Resolution of pain
Number of subjects: 220
Study: 33526484

Group type: EXPERIMENTAL
Intervention: Oxfendazole (0.5 to 60 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxfendazole metabolites (oxfendazole sulfone and fenbendazole)
Number of subjects: 0
Study: 36440393

Group type: EXPERIMENTAL
Intervention: Independent Supported Housing (ISH)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Housing as usual (HAU)
Number of subjects: 141
Study: 34018413

Group type: EXPERIMENTAL
Intervention: Seroprevalence testing for rickettsial infections
Number of subjects: 2360

Group type: EXPERIMENTAL
Intervention: Seroprevalence testing for spotted fever group rickettsiae
Number of subjects: 2360

Group type: EXPERIMENTAL
Intervention: Seroprevalence testing for scrub typhus
Number of subjects: 2360

Group type: EXPERIMENTAL
Intervention: Seroprevalence testing for typhus group rickettsiae
Number of subjects: 2360

Group type: EXPERIMENTAL
Intervention: Seroprevalence in Tripura
Number of subjects: 2360

Group type: EXPERIMENTAL
Intervention: Seroprevalence in Assam
Number of subjects: 2360

Group type: EXPERIMENTAL
Intervention: Seroprevalence in Meghalaya
Number of subjects: 2360

Group type: EXPERIMENTAL
Intervention: Seroprevalence in adults aged 18-45 years
Number of subjects: 2360
Study: 33486643

Group type: EXPERIMENTAL
Intervention: Risk prediction score based on 7 factors (stoma creation, Peritoneal Cancer Index score ≥15, hyponatremia, in-hospital major complication, preoperative chemotherapy, anemia, discharge to nursing home)
Number of subjects: 1068

Group type: EXPERIMENTAL
Intervention: Risk prediction score
Number of subjects: 1068
Study: 32152693

Group type: EXPERIMENTAL
Intervention: Intravenous infusion with indwelling needles
Number of subjects: 110

Group type: COMPARATOR
Intervention: Intravenous infusion with steel needles
Number of subjects: 110
Study: 35337021

Group type: EXPERIMENTAL
Intervention: Glecaprevir/Pibrentasvir + Ribavirin for 4 weeks
Number of subjects: 27

Group type: COMPARATOR
Intervention: Glecaprevir/Pibrentasvir for 8 weeks
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Baseline viral load <2 mill IU/mL
Number of subjects: 27
Study: 36243227

Group type: EXPERIMENTAL
Intervention: Direct consultations with a medical physicist during treatment simulation and before the first treatment.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (no direct consultations with a medical physicist).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Direct consultations with a medical physicist.
Number of subjects: 0
Study: 34062000

Group type: EXPERIMENTAL
Intervention: Automatic segmentation and quantification of epicardial adipose tissue (EAT) using a multi-slice deep neural network and deformable model.
Number of subjects: 103

Group type: COMPARATOR
Intervention: Manual delineation by two radiology experts.
Number of subjects: 103
Study: 32788139

Group type: EXPERIMENTAL
Intervention: SMS text reminders sent two days before appointments and an additional reminder seven days after missed appointments.
Number of subjects: 9368

Group type: COMPARATOR
Intervention: Control group (no SMS reminders).
Number of subjects: 9368
Study: 36169959

Group type: EXPERIMENTAL
Intervention: Dimethyl Fumarate (DMF)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Interferon β-1a (IFNβ-1a)
Number of subjects: 150
Study: 32324840

Group type: EXPERIMENTAL
Intervention: Individualized homeopathic treatment (IHT) with homeopathic remedies at 30C (10-60) and 200C (10-400) dilutions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluoxetine treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 0
Study: 36494544

Group type: EXPERIMENTAL
Intervention: Identification and Referral to Improve Safety (IRIS) intervention adapted for general dental practices
Number of subjects: 0
Study: 33662894

Group type: EXPERIMENTAL
Intervention: Cenobamate 100 mg once daily
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Cenobamate 200 mg once daily
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Cenobamate 400 mg once daily
Number of subjects: 397

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 397
Study: 32040868

Group type: EXPERIMENTAL
Intervention: Doxepin cream (5%) for 7 days
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo cream for 7 days
Number of subjects: 48
Study: 33684953

Group type: EXPERIMENTAL
Intervention: 1 tablet of metformin SR 1000 mg and 1 tablet of TQ 50 mg once daily (T1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1 tablet of metformin SR 1000 mg and 2 tablets of TQ 50 mg once daily (T2)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 1 tablet of metformin SR 1000 mg only (R)
Number of subjects: 60
Study: 33164575

Group type: EXPERIMENTAL
Intervention: Sitting with 3-min bouts of simple resistance activities (SRA) every 30 minutes (SRA3)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sitting with 6-min bouts of simple resistance activities (SRA) every 60 minutes (SRA6)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Uninterrupted sitting (SIT)
Number of subjects: 24
Study: 32248191

Group type: EXPERIMENTAL
Intervention: Healthcare consumption and costs for women with endometriosis
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Healthcare consumption and costs for women under 30 years
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Work-related outcomes for women with endometriosis
Number of subjects: 431
Study: 34217808

Group type: EXPERIMENTAL
Intervention: CAEP Acute AF/AFL Best Practices Checklist
Number of subjects: 718

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 718
Study: 32027810

Group type: EXPERIMENTAL
Intervention: Ultra-low dosage of rituximab (200 mg single infusion)
Number of subjects: 8
Study: 36293985

Group type: EXPERIMENTAL
Intervention: HIIT + RT
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: RT + HIIT
Number of subjects: 18
Study: 33370140

Group type: EXPERIMENTAL
Intervention: Supporter help with calling health care providers
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Supporter help with remembering medical appointments
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Supporter help with giving directions when blood sugars were low
Number of subjects: 239

Group type: COMPARATOR
Intervention: Patient perception of supporter helpfulness
Number of subjects: 239
Study: 35945573

Group type: EXPERIMENTAL
Intervention: High-quality lactation room
Number of subjects: 328

Group type: COMPARATOR
Intervention: Low-quality lactation room
Number of subjects: 328
Study: 33532037

Group type: EXPERIMENTAL
Intervention: Resistance training (RT) circuit program, 6 stations, 3 days/week for 12 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 36
Study: 32847833

Group type: EXPERIMENTAL
Intervention: Fetal haemoglobin (HbF) levels
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Lowest quartile of HbF
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: HbF levels in full statistical model
Number of subjects: 452
Study: 35333885

Group type: EXPERIMENTAL
Intervention: Vitamin D3-fortified fruit juices containing 4000 IU (100 mcg) daily for 8 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo-fruit juices daily for 8 weeks
Number of subjects: 120
Study: 33530982

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 44

Group type: COMPARATOR
Intervention: Sitagliptin
Number of subjects: 44
Study: 36288843

Group type: EXPERIMENTAL
Intervention: Dry needling (DN) intervention, performed thrice a week for 2 weeks, in addition to conventional treatment
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional treatment, performed once a day for 40 min, five times a week for 2 weeks
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Dry needling (DN) intervention
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 44
Study: 33333459

Group type: EXPERIMENTAL
Intervention: Clinical decision support alert for carbohydrate-containing medication orders
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Clinical decision support alert
Number of subjects: 280
Study: 35435565

Group type: EXPERIMENTAL
Intervention: Machine learning models for predicting postoperative remission at 3 months
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Machine learning models for predicting remission at last visit
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Machine learning models for predicting resistance to somatostatin receptor ligands (SRL)
Number of subjects: 152
Study: 34031278

Group type: EXPERIMENTAL
Intervention: Pudendal nerve block anesthesia + stepwise dissection and incisional local anesthesia (Group A)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Bilateral pudendal nerve block anesthesia (Group B)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Pudendal nerve block anesthesia + local infiltration anesthesia (Group C)
Number of subjects: 300
Study: 32942054

Group type: EXPERIMENTAL
Intervention: In-person method (n = 46)
Number of subjects: 1113

Group type: COMPARATOR
Intervention: Digital method (n = 92)
Number of subjects: 1113

Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 1113

Group type: EXPERIMENTAL
Intervention: Economic evaluation
Number of subjects: 1113
Study: 34184202

Group type: EXPERIMENTAL
Intervention: Intradialytic exercise training (IET) at 60% of pre‐assessed maximum aerobic power, 3 times per week for 7 months
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Intradialytic exercise training (IET)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control Group (no exercise)
Number of subjects: 44
Study: 33830998

Group type: EXPERIMENTAL
Intervention: 850 mg metformin three times daily
Number of subjects: 390

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 390
Study: 35750726

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: MI aided by the interactive patient communication tool, the Cariogram
Number of subjects: 512

Group type: COMPARATOR
Intervention: MI (Group II)
Number of subjects: 512

Group type: COMPARATOR
Intervention: MI aided by the interactive patient communication tool, the Cariogram (Group III)
Number of subjects: 512

Group type: COMPARATOR
Intervention: Oral health education (Group I)
Number of subjects: 512
Study: 33541896

Group type: EXPERIMENTAL
Intervention: Arterial spin-labeling MRA
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced time-resolved MRA
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Combined arterial spin-labeling MRA and contrast-enhanced time-resolved MRA
Number of subjects: 29
Study: 35261289

Group type: EXPERIMENTAL
Intervention: Milrinone
Number of subjects: 142

Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 142
Study: 32965585

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg twice daily
Number of subjects: 2055

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 5 mg twice daily
Number of subjects: 2055

Group type: COMPARATOR
Intervention: Enoxaparin 1 mg/kg twice daily
Number of subjects: 2055
Study: 33612031

Group type: EXPERIMENTAL
Intervention: RT + NS
Number of subjects: 40

Group type: COMPARATOR
Intervention: RT
Number of subjects: 40

Group type: COMPARATOR
Intervention: NS
Number of subjects: 40

Group type: COMPARATOR
Intervention: RT + placebo
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study: 34845600

Group type: EXPERIMENTAL
Intervention: Lactocare® (two times daily for 12 weeks)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo (two times daily for 12 weeks)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Lactocare®
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 33179818

Group type: EXPERIMENTAL
Intervention: Pump therapy with continuous glucose monitoring offering low glucose suspend (LGS)
Number of subjects: 144
Study: 33931361

Group type: EXPERIMENTAL
Intervention: Superselective RAPN (SS-RAPN) with near-infrared fluorescence (NIRF)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional RAPN with renal artery early unclamping
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Superselective RAPN (SS-RAPN)
Number of subjects: 50
Study: 32799429

Group type: COMPARATOR
Intervention: Primary Healthcare (PHC)
Number of subjects: 1386

Group type: EXPERIMENTAL
Intervention: Secondary Healthcare (SHC)
Number of subjects: 1386

Group type: COMPARATOR
Intervention: PHC
Number of subjects: 1386

Group type: EXPERIMENTAL
Intervention: SHC
Number of subjects: 1386

Group type: EXPERIMENTAL
Intervention: Age and diabetes duration
Number of subjects: 1386

Group type: EXPERIMENTAL
Intervention: Poor glycemic control, hyperlipidemia, hypertension
Number of subjects: 1386

Group type: EXPERIMENTAL
Intervention: Obesity and reduced physical activity
Number of subjects: 1386
Study: 34843843

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO) treatment with 30 pre- and 10 postoperative exposures at 243 kPa for 90 min each
Number of subjects: 65

Group type: COMPARATOR
Intervention: Surgical removal of necrotic bone only (Control group)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO) treatment
Number of subjects: 65

Group type: COMPARATOR
Intervention: Standard care (Control group)
Number of subjects: 65
Study: 34033889

Group type: EXPERIMENTAL
Intervention: CRPA identified through surveillance cultures (51.4%) and clinical cultures (49.6%)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Infections in kidney transplant recipients
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Risk factors for CRPA acquisition
Number of subjects: 37
Study: 35300657

Group type: EXPERIMENTAL
Intervention: FDI criteria
Number of subjects: 185

Group type: COMPARATOR
Intervention: CARS criteria
Number of subjects: 185
Study: 32920607

Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide gel (Opalescence, Ultradent Products) (2 h/day, for 14 days)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 40% hydrogen peroxide gel (Opalescence Boost, Ultradent Products) (three bleaching sessions, once a week, 45 min/session)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: whitening rinse (Listerine Whitening Extreme, Johnson & Johnson) (2 min/day, for 14 days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: distilled water (control)
Number of subjects: 40
Study: 36331921

Group type: EXPERIMENTAL
Intervention: Open-label placebo treatment
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 8
Study: 33537745

Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 9891

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9891
Study: 33114392

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 86
Study: 35461522

Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted cH8/1N1-cH5/1N1-cH11/1N1
Number of subjects: 507

Group type: COMPARATOR
Intervention: IIV4-placebo-IIV4
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: non-adjuvanted cH5/1N1-placebo-cH8/1N1
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: Adjuvanted SUIV
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: Non-adjuvanted SUIV
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: All chimeric vaccines
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 507
Study: 34558940

Group type: EXPERIMENTAL
Intervention: randomized measurement settings generated by a discrete group of fermionic Gaussian unitaries, implementable with linear-depth circuits
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: randomized measurement settings with particle-number symmetry
Number of subjects: 0
Study: 35717987

Group type: EXPERIMENTAL
Intervention: Relugolix combination therapy (relugolix 40 mg, estradiol 1 mg, norethisterone acetate 0.5 mg)
Number of subjects: 1261

Group type: COMPARATOR
Intervention: Relugolix combination therapy
Number of subjects: 1261
Study: 32152174

Group type: EXPERIMENTAL
Intervention: cTBS+iTBS
Number of subjects: 36

Group type: COMPARATOR
Intervention: sham cTBS+iTBS
Number of subjects: 36

Group type: COMPARATOR
Intervention: sham cTBS+sham iTBS
Number of subjects: 36
Study: 36494245

Group type: EXPERIMENTAL
Intervention: Desflurane anesthesia (Group D)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Total intravenous anesthesia (Group T)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Both anesthesia methods (Group T and Group D)
Number of subjects: 74
Study: 33549463

Group type: EXPERIMENTAL
Intervention: Patient-Reported Functional Status (PRFS)
Number of subjects: 13045

Group type: EXPERIMENTAL
Intervention: Eastern Cooperative Oncology Group (ECOG)
Number of subjects: 13045

Group type: COMPARATOR
Intervention: Model with PRFS
Number of subjects: 13045

Group type: COMPARATOR
Intervention: Model with ECOG
Number of subjects: 13045

Group type: COMPARATOR
Intervention: Model with clinical characteristics only
Number of subjects: 13045
Study: 32087032

Group type: EXPERIMENTAL
Intervention: Oral bacterial lysate (heat-killed Escherichia coli and Enterococcus faecalis)
Number of subjects: 606

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 606
Study: 36156542

Group type: EXPERIMENTAL
Intervention: Glucosamine and chondroitin sulfate supplementation for 4 weeks in addition to manual therapy and resistance exercise training.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Manual therapy and resistance exercise training.
Number of subjects: 24
Study: 34444594

Group type: EXPERIMENTAL
Intervention: Therapeutic exercises + Pain Neuroscience Education (PNE)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Therapeutic exercises alone
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72